ATG4A

Cysteine protease ATG4A · Q8WYN0 · ATG4A on Sugi Atlas →

43 patent compounds predicted against ATG4A, 37 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tioconazole (SCHEMBL41354)	1.00	1/20
Tioconazole (SCHEMBL41355)	1.00	1/20
Tioconazole (SCHEMBL3682098)	1.00	1/20
Tioconazole (SCHEMBL3682100)	1.00	1/20
Tioconazole (SCHEMBL29408808)	1.00	1/20
Tioconazole (SCHEMBL29881791)	1.00	1/20
Tioconazole (SCHEMBL29882046)	1.00	1/20
Tioconazole (SCHEMBL3722115)	0.98	1/20
Tioconazole (SCHEMBL7165886)	0.98	1/20
Tioconazole (SCHEMBL7165888)	0.98	1/20
Tioconazole (SCHEMBL9441817)	0.91	1/20
Tioconazole (SCHEMBL7161218)	0.89	1/20
Tioconazole (SCHEMBL5156489)	0.86	1/20
Tioconazole (SCHEMBL5156492)	0.86	1/20
Tioconazole (SCHEMBL2153130)	0.84	1/20
Tioconazole (SCHEMBL28113548)	0.83	1/20
SCHEMBL18309801	0.81	1/20
Tioconazole (SCHEMBL28113545)	0.81	1/20
SCHEMBL9064912	0.71	1/20
SCHEMBL15587019	0.70	1/20

Clinical trials — most relevant to ATG4A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy	PHASE2/PHASE3	UNKNOWN
Azithromycin Plus Hydroxychloroquine for COVID-19 Infection	PHASE3	WITHDRAWN
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)	PHASE1/PHASE2	RECRUITING
Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients	PHASE2	UNKNOWN
ATG Individualized Dosing Model in URD-PBSCT.	PHASE2	RECRUITING
Clostridium Butyricum in Stenosing Crohn's Desease	PHASE1/PHASE2	NOT_YET_RECRUITING
Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients	PHASE2	COMPLETED
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer	PHASE1/PHASE2	COMPLETED
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors	PHASE1	RECRUITING
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction	EARLY_PHASE1	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Autophagy Bladder Cancer	nan	UNKNOWN
The Influence of Autophagy on Fatty Liver	nan	UNKNOWN
Fasting, Exercise, and Diet to Activate Autophagy in Depression	nan	NOT_YET_RECRUITING
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population	nan	COMPLETED
2-A-Day Study: Twice a Day Meals Study.	nan	COMPLETED
Predicting Pancreatic Necrosis Using mitDNA	nan	UNKNOWN
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease	nan	UNKNOWN
Time Course for Fasting-induced Autophagy in Humans	nan	WITHDRAWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Autophagy/Apoptosis Balance in Placental Vascular Pathologies	nan	RECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Muscle Insulin Resistance in Aging (Mirage)	nan	ACTIVE_NOT_RECRUITING
Autophagy, Oxidative Stress and Hippo Signaling in Human Aortic Aneurysm	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Evaluation of Serum Autophagic Biomarkers in the Acute Response to Walking and Cycling in Healthy Male Individuals	nan	ENROLLING_BY_INVITATION
Intermittent Fasting for Pancreatitis	nan	NOT_YET_RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ATG4A binder may also engage these)

Protein	Name	Similarity
Q5R699	—	1.000	Q5R699 →
Q6PZ05	—	1.000	Q6PZ05 →
Q5ZIW7	—	1.000	Q5ZIW7 →
Q8C9S8	—	0.998	Q8C9S8 →
Q6GPU1	—	0.985	Q6GPU1 →
Q6DG88	—	0.984	Q6DG88 →
Q640G7	—	0.982	Q640G7 →
Q68EP9	—	0.979	Q68EP9 →
Q811C2	—	0.978	Q811C2 →
Q5XH30	—	0.977	Q5XH30 →
Q96DT6	—	0.976	Q96DT6 →
Q8BGE6	—	0.971	Q8BGE6 →
Q6NX27	—	0.970	Q6NX27 →
Q8BML1	—	0.967	Q8BML1 →
A0A0R4IMY7	—	0.965	A0A0R4IMY7 →
F1RA39	—	0.965	F1RA39 →
P98192	—	0.964	P98192 →
Q91YH5	—	0.964	Q91YH5 →
Q8NHH9	—	0.964	Q8NHH9 →
Q9UPR0	—	0.963	Q9UPR0 →
O94851	—	0.963	O94851 →
Q6PA06	—	0.963	Q6PA06 →
O88509	—	0.963	O88509 →
TRPM6	Transient receptor potential cation channel subfamily M member 6	0.963	landscape →
Q8K394	—	0.963	Q8K394 →
A0AUR5	—	0.963	A0AUR5 →
Q925B3	—	0.962	Q925B3 →
Q8R424	—	0.962	Q8R424 →
F1MF74	—	0.962	F1MF74 →
Q62688	—	0.961	Q62688 →